Tweet
<img alt="" height="1" width="1" />
Merck and Endocyte's ovarian cancer drug fails in trial
Reuters
(Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening. The trial was testing the drug, vintafolide, in combination ...
Endocyte Reports First Quarter Financial Results and Provides Clinical UpdateMarketWatch
Endocyte, Inc. (ECYT) Tops Q1 EPS by 5c; Reports Halt of PROCEED Trial (MRK)StreetInsider.com (subscription)
Endocyte (ECYT) Releases Quarterly Earnings Results, Beats Estimates By ...Zolmax
all 4 news articles »
More...